Clinical study of olaparil,bevacizumab and platinum chemotherapy regimen for ovarian cancer
Objective:To investigate the clinical study of olaparil and bevacizumab combined with platinum chemotherapy for o-varian cancer.Methods:A total of 90 ovarian cancer patients admitted to the 989th Hospital of the Joint Logistics Support Force from July 2021 to January 2024 were selected,and 45 cases were obtained in the study group and the control group,re-spectively,by using the propensity score matching method in a 1:1 ratio.The control group was given bevacizumab combined with cisplatin and paclitaxel chemotherapy,and the study group was given olapalil tablets orally,all for four courses.Objective response rates(ORR)and pre-and post-treatment serum angiogenin-2(Ang-2),vascular endothelial growth factor(VEGF),human epididymal protein 4(HE4),immune index level,and the incidence of toxic side effects during medication were com-pared.Results:The ORR of the study group was 68.89%,higher than the control group of 44.44%(P<0.05);after treat-ment,VE GF,Ang-2,and HE4 were significantly lower than the study group(P<0.05);CD3+,CD4+and CD4+/CD8+were higher than the study group(P<0.05);There was no significant difference in the incidence of toxic side effects between the two groups(P>0.05).Conclusion:Olaapil and bevacizumab combined with platinum chemotherapy can effectively im-prove the recent efficacy of ovarian cancer patients,improve the level of endothelium-related factors and immune function indi-cators in blood vessels,and the safety is controllable.
国家科技期刊平台
NSTL
万方数据
